J Dick1, N Lang1, A Slynko2, A Kopp-Schneider2, C Schulz1, A Dimitrakopoulou-Strauss3, A H Enk1, J C Hassel1. 1. Department of Dermatology & National Centre for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany. 2. German Cancer Research Centre DKFZ, Department of Biostatistics, Heidelberg, Germany. 3. Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Centre Heidelberg, Germany.
Abstract
BACKGROUND: Ipilimumab is a cytotoxic T-lymphocyte antigen-4 antibody that enhances T-cell activity and proliferation. METHODS: In a retrospective analysis of 86 patients the clinical benefits of ipilimumab treatment were correlated with laboratory and clinical data. RESULTS: A lactate dehydrogenase (LDH) value within the normal range before the start of therapy was significantly correlated with better OS (p ≤ 0.009). An increase in LDH level after two cycles was indicative of a poor outcome, and was significantly negatively correlated with treatment response and overall survival and progression-free survival. 42% of all patients suffered from autoimmune toxicity (CTCAE grades 2-4). The occurrence of autoimmune toxicity clearly correlated with clinical benefit. CONCLUSION: Changes in LDH level and side effects correlate with response to therapy and survival.
BACKGROUND:Ipilimumab is a cytotoxic T-lymphocyte antigen-4 antibody that enhances T-cell activity and proliferation. METHODS: In a retrospective analysis of 86 patients the clinical benefits of ipilimumab treatment were correlated with laboratory and clinical data. RESULTS: A lactate dehydrogenase (LDH) value within the normal range before the start of therapy was significantly correlated with better OS (p ≤ 0.009). An increase in LDH level after two cycles was indicative of a poor outcome, and was significantly negatively correlated with treatment response and overall survival and progression-free survival. 42% of all patients suffered from autoimmune toxicity (CTCAE grades 2-4). The occurrence of autoimmune toxicity clearly correlated with clinical benefit. CONCLUSION: Changes in LDH level and side effects correlate with response to therapy and survival.
Entities:
Keywords:
LDH; autoimmune side effects; ipilimumab; melanoma
Authors: Jenna L Collier; Sarah A Weiss; Kristen E Pauken; Debattama R Sen; Arlene H Sharpe Journal: Nat Immunol Date: 2021-06-17 Impact factor: 31.250
Authors: Jessica C Hassel; Huanhuan Jiang; Carolin Bender; Julia Winkler; Alexandra Sevko; Ivan Shevchenko; Niels Halama; Antonia Dimitrakopoulou-Strauss; Walter E Haefeli; Dirk Jäger; Alexander Enk; Jochen Utikal; Viktor Umansky Journal: Oncoimmunology Date: 2017-05-16 Impact factor: 8.110